Table 3.

Comparing the characteristics of drug with competitors

Name of Drug	Mechanism of action	Adverse events	Efficacy	Phase
Ibrutinib[70]	Irreversible BTK inhibitor	Diarrhea, fatigue, URTI and Pneumonia	ORR 71% (CR+PR) in relapsed ant treatment naïve patients with CLL	Approved for relapse/refractory CLL
ONO-4059[77]	2nd generation irreversible BTK inhibitor	Diarrhea, skin rash, febrile neutropenia	ORR 70% (PR; 29%, PRL; 71%) in relapsed refractory CLL patients	Phase 1/ 2 clinical trial
CC-292[68]	2nd generation irreversible BTK inhibitor	Diarrhea, fatigue, neutropenia, thrombocytopenia, headache, and URTIs	PR 40% and nodal response 64.5%.	Phase I clinical trial
Idelalisib[50]	PI3K-delta inhibitor	Diarrhea, fatigue, neutropenia, transaminases, pneumonitis and lymphocytic colitis.	ORR 72% and PFS 15.8 months in relapsed CLL, PFS improved in those treated at doses of ≥ 150 mg BID	Approved for relapsed CLL, in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
AMG 319[78]	PI3K-delta inhibitor	Colitis, hemolysis, anemia, infection and leucocytosis	PR 7%, 75% had nodal response	Phase 1 trial in relapsed or refractory lymphoid malignancies
Fostamatinib[45]	Spleen tyrosine kinase inhibitor	Diarrhea, fatigue, cytopenia and hypertension	ORR 22% and PFS 4.2 months in relapse/refractory B-NHL	Phase 1/ 2 clinical trial
ABT-199[53]	Bcl-2 inhibitor	Diarrhea, neutropenia, fatigue, URTIs and tumor lysis syndrome	ORR 84% (CR; 21% +PR; 63%) in relapsed refractory patients with NHL	Phase 1/ 2 clinical trial